Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Protective effects of sacubitril valsartan on diabetic kidney disease
jRCTs031240742Recruiting
- Sponsor
- Chiba University Hospital
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of sacubitril + valsartan in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chiba University Hospital. Primary endpoint: Primary: Change in urinary albumin/creatinine ratio at 28 weeks. Started Mar 2025; status: recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs031240742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240742.